Drug Delivery Systems
NeuroOne Partners with University of Minnesota to Advance Targeted Epilepsy Treatment Platform
NeuroOne Medical Technologies is collaborating with the University of Minnesota to develop a brain drug delivery system that could revolutionize epilepsy treatment by delivering therapies directly to seizure sites, potentially improving efficacy while reducing side effects.
Nutriband CEO Discusses AVERSA Technology's Role in Addressing Opioid Crisis on Podcast
Nutriband Inc. CEO Gareth Sheridan highlighted the company's AVERSA abuse-deterrent transdermal technology on a podcast, emphasizing its potential to reduce misuse of high-risk drugs like fentanyl while maintaining patient access.
Oncotelic and Sapu Bioscience Define Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics and Sapu Bioscience have published a landmark review establishing sub-15 nm nanoparticles as a breakthrough drug delivery platform capable of overcoming limitations of current therapies through enhanced tissue penetration and reduced toxicity.
Nanomedicine Breakthroughs Reshape Cancer Treatment Through Enhanced Drug Delivery
Advances in nanomedicine delivery systems are addressing critical limitations in cancer therapy by improving drug bioavailability and targeting while reducing toxicity, potentially transforming treatment standards across the oncology landscape.
Nutriband Advances Abuse-Deterrent Fentanyl Patch Toward FDA Submission Following Regulatory Feedback
Nutriband Inc. has received critical FDA guidance confirming the regulatory pathway for its AVERSA™ Fentanyl abuse-deterrent transdermal system, marking a significant step forward in addressing the opioid crisis through innovative pharmaceutical technology.
Branded Legacy Advances Engineering of Air-Driven Intranasal Drug Delivery Platform
Branded Legacy's subsidiary BioLegacy Evaluative Group has begun engineering a unitary device mold for its proprietary air-driven intranasal drug delivery system, marking a significant step toward scalable production of affordable addiction treatment solutions including inhaled naloxone.
Nutriband's AVERSA Fentanyl Patch Advances Toward 2026 FDA Submission with $200M Market Potential
Nutriband Inc. is progressing with its abuse-deterrent fentanyl patch technology that could generate up to $800 million in annual sales while addressing the opioid crisis through tamper-resistant transdermal delivery.
Oncotelic's 20nm Nanoparticle Technology Enters Human Trials for Enhanced Breast Cancer Treatment
Oncotelic Therapeutics has begun human trials for its 20nm nanoparticle formulation of Everolimus, representing a significant advancement in cancer drug delivery that could dramatically improve tumor targeting and treatment efficacy.
Nutriband Chairman to Present at Emerging Growth Conference, Highlighting Abuse-Deterrent Technology
Nutriband Inc. Chairman Serguei Melnik will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, showcasing the company's AVERSA abuse-deterrent technology for transdermal pharmaceutical products.
Branded Legacy Subsidiary Files Provisional Patent for Innovative Intranasal Drug Delivery Platform
Branded Legacy's subsidiary BioLegacy Evaluative Group has filed a provisional patent for an air-powered intranasal drug delivery device that could revolutionize treatment for opioid overdoses and other conditions requiring precise nasal administration.
Nutriband to Present AVERSA Technology Strategy at MicroCap Rodeo Conference
Nutriband Inc.'s upcoming presentation at the MicroCap Rodeo Conference highlights the company's strategic direction for its innovative AVERSA abuse-deterrent technology platform, which addresses critical safety concerns in transdermal pharmaceutical delivery.
Nutriband Secures FDA Meeting for Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. has obtained FDA approval for a Type C meeting regarding its AVERSA™ abuse-deterrent fentanyl patch technology, marking a significant regulatory milestone in addressing opioid abuse through transdermal pharmaceutical innovation.
Nutriband Showcases AVERSA™ Abuse-Deterrent Technology Addressing Opioid Crisis at Emerging Growth Conference
Nutriband Inc. presented its AVERSA™ abuse-deterrent transdermal technology at the August 2025 Emerging Growth Conference, projecting peak annual sales of $200 million for its fentanyl patch upon FDA approval with potential to exceed $800 million, offering a critical solution to the ongoing opioid epidemic.
Nutriband Inc. to Showcase AVERSA(TM) Technology at Emerging Growth Conference
Nutriband Inc. (NASDAQ: NTRB) will present its AVERSA(TM) abuse-deterrent technology at the Emerging Growth Conference, highlighting its potential to revolutionize transdermal pharmaceutical products.
GeoVax Explores Needle-Free Vaccine Delivery with Vaxxas Technology
GeoVax Labs, Inc. initiates a research program to evaluate the potential of a needle-free, self-administered GEO-MVA vaccine using Vaxxas' HD-MAP technology, aiming to enhance global immunization efforts.
Nutriband Inc. Advances Abuse-Deterrent Drug Delivery with AVERSA Technology
Nutriband Inc. is pioneering in the development of abuse-deterrent transdermal patches, aiming to address critical public health needs with its AVERSA Fentanyl and Buprenorphine candidates.
Creative Biolabs Advances Liposome Technology for Enhanced Drug Delivery
Creative Biolabs is pioneering liposome technology to improve drug delivery systems, offering innovative solutions for pharmaceutical industries and beyond.
Nutriband Inc. Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
Nutriband Inc. is pioneering a novel transdermal delivery system for buprenorphine, aiming to address the opioid epidemic with safer treatment options, potentially revolutionizing pain and addiction therapies.
Nutriband Inc.'s AVERSA Technology Poised for FDA Approval with Significant Market Potential
Nutriband Inc.'s innovative AVERSA abuse-deterrent patch technology, targeting the misuse of transdermal patches like fentanyl, is on its way to FDA approval, with an estimated annual market potential of $800 million.
Nutriband Seeks to Revolutionize Transdermal Pain Management Through Innovative Abuse-Deterrent Technology
Nutriband is developing a groundbreaking transdermal drug delivery platform aimed at addressing pain management challenges in the wake of the opioid crisis, focusing on creating safer, more accessible opioid therapies.
Nutriband Advances Opioid Patch Technology with Potential Abuse-Deterrent Solution
Nutriband is making significant progress toward commercializing its AVERSA Fentanyl technology, partnering with Kindeva Drug Delivery to develop a potentially groundbreaking opioid pain patch with abuse-deterrent properties.
Nutriband Expands Pharma Footprint with Strategic Partnerships
Nutriband Inc. strengthens its market position through strategic alliances with Charlotte FC and Kindeva Drug Delivery, focusing on its innovative abuse-deterrent transdermal drug delivery technology.
Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch to Address Opioid Crisis
Nutriband Inc. has developed AVERSA™ Fentanyl, a technologically advanced transdermal patch designed to provide effective pain management while mitigating potential opioid abuse risks. The innovation represents a strategic approach to addressing the ongoing public health challenge of the opioid epidemic.
Nutriband Advances Abuse-Deterrent Transdermal Drug Technology, Eyes 2025 Commercialization
Nutriband is positioning itself for potential market expansion by developing innovative abuse-deterrent transdermal pharmaceutical products with projected peak annual sales exceeding $330 million for its Fentanyl and Buprenorphine patches.
Nutriband Develops Innovative Abuse-Deterrent Transdermal Drug Technology
Nutriband Inc. is advancing pharmaceutical safety through its AVERSA technology, which aims to prevent drug abuse and misuse in transdermal patches while maintaining patient access to critical medications.
Nutriband Strengthens Intellectual Property for Abuse-Deterrent Drug Delivery Technology
Nutriband secures new U.S. trademark and international patents for its AVERSA™ transdermal drug delivery platform, positioning the company to target a significant market opportunity in abuse-deterrent pharmaceuticals.
Major Healthcare Partnership Aims to Revolutionize Oral Thrush Treatment
A new three-way partnership between Shear Kershman Labs, Texas A&M College of Dentistry, and Innovative MedTech Inc. promises to transform oral healthcare through an innovative drug delivery system that could benefit millions of patients suffering from oral thrush.